blood filtering – A small pilot study suggests filtering sFlt-1 from pregnant people’s blood may be safe and modestly lower blood pressure—offering a potential path beyond delivery.
Preeclampsia is one of the most dangerous complications of pregnancy, and for many patients there’s been little more to do than deliver early.
In the first paragraph of Misryoum’s latest look at the science, the focus is clear: blood filtering aimed at a pregnancy-linked protein called sFlt-1 may offer a more targeted approach to help patients stabilize before delivery.
Preeclampsia typically shows up after the midpoint of pregnancy with high blood pressure and protein in the urine. and it can quickly become life-threatening for both parent and baby.. Because there’s no widely established treatment that directly addresses the underlying drivers of the condition. clinicians often have to choose between managing symptoms and getting the pregnancy delivered—sometimes prematurely—so the risk doesn’t escalate.
The new work Misryoum reviewed centers on a pilot clinical study in which 16 women with preterm preeclampsia underwent a hospital-based blood filtering procedure.. The approach is designed to remove sFlt-1, a protein associated with the disease, from the bloodstream.. Rather than adding an antibody directly into circulation—an idea the researchers considered—this method filters the targeted molecule out and then returns the rest of the blood to the patient.. That “work-around” is intended to reduce concerns about what might cross the placenta.
# Blood filtering as a “turn-off” for sFlt-1
Blood filtering already exists in medicine for some kidney conditions, but the pregnancy setting is different.. Misryoum notes that the research team treated blood filtering less like an unproven wellness trend and more like a controlled. temporary medical intervention: remove one problematic protein. measure changes. and stop the machine if complications arise.
Before moving to pregnant participants, the protocol was tested in baboons and in people who were not pregnant.. Only afterward did the trial enroll women admitted to the hospital with preterm preeclampsia.. In the first phase, seven participants received one session lasting roughly one to two hours.. In the second phase. nine were eligible for multiple cycles—ranging from one to three—depending on eligibility criteria and the study plan.
Across the study. the goal wasn’t to claim a cure from such a small trial; it was to establish whether the intervention could be done safely and whether it meaningfully influenced disease biology.. After treatment cycles in the second phase, average sFlt-1 levels fell by nearly 17%.. At the same time. blood pressure was described as stabilizing. and pregnancies in the treated group were prolonged by about 10 days after admission—roughly twice as long as researchers expected without the intervention.
# Why gaining days matters in preterm preeclampsia
For families and clinicians, every additional day of gestation can shift what comes next.. Misryoum emphasizes the practical reality: the nearer a baby is to full-term, the fewer complications typically follow from prematurity.. The study’s investigators framed “extension” as a key component of the therapeutic ambition—getting pregnancies from around 29 to 32 weeks toward longer windows such as 34 or 36 weeks when possible.
That matters because preeclampsia doesn’t just raise blood pressure; it can also affect multiple organ systems and the placenta’s ability to support fetal growth.. If clinicians can stabilize the condition long enough. they may reduce the pressure to deliver immediately. allowing time for fetal development and safer neonatal outcomes.
Still, a single pilot study can’t answer every question.. Misryoum flags the central limitation: even if the early results are promising, they need verification in larger randomized trials.. Researchers not involved in the work described the findings as intriguing and consistent with existing understandings of how preeclampsia develops—especially the role of sFlt-1 in disrupting pregnancy-related vascular balance.
# The bigger challenge: safety, timing, and scale
Misryoum’s editorial take is that the real scientific challenge now is not whether the concept is clever—it’s whether it can be made reliably safe. scalable. and effective across the full range of patients with preeclampsia.. The researchers themselves pointed toward next steps: running a randomized controlled trial. improving understanding of safety. and exploring whether treatment could begin earlier in pregnancy—before symptoms become severe.
That “earlier” piece could be decisive.. In many conditions, intervening late reduces potential benefit because the cascade is already underway.. With preeclampsia. starting therapy before the parent becomes critically ill might increase the chance that stabilizing the protein driver translates into sustained improvement.
The team also indicated interest in whether other proteins linked to preeclampsia could be filtered using similar methods. If the disease involves multiple molecular pathways, a future strategy could involve targeting more than one driver—though that would require careful validation.
For now. the study offers something that’s been missing in preeclampsia care: a move toward an evidence-based. biology-targeted treatment rather than a purely delivery-based endpoint.. Misryoum will be watching closely as larger trials aim to confirm whether blood filtering can do more than stabilize lab markers—whether it can meaningfully change outcomes for mothers and babies when preeclampsia strikes early.